Davis R M Inc. Has $34.23 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Davis R M Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 22.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 44,334 shares of the company’s stock after purchasing an additional 8,098 shares during the quarter. Davis R M Inc.’s holdings in Eli Lilly and Company were worth $34,225,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in LLY. Principal Financial Group Inc. boosted its stake in Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after purchasing an additional 60,306 shares during the last quarter. XML Financial LLC boosted its stake in Eli Lilly and Company by 1.0% during the 3rd quarter. XML Financial LLC now owns 1,775 shares of the company’s stock valued at $1,572,000 after purchasing an additional 17 shares during the last quarter. Arvest Investments Inc. boosted its stake in Eli Lilly and Company by 5.1% during the 3rd quarter. Arvest Investments Inc. now owns 870 shares of the company’s stock valued at $771,000 after purchasing an additional 42 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in Eli Lilly and Company by 0.9% during the 3rd quarter. Los Angeles Capital Management LLC now owns 468,385 shares of the company’s stock valued at $414,961,000 after purchasing an additional 4,390 shares during the last quarter. Finally, Ashton Thomas Securities LLC boosted its stake in Eli Lilly and Company by 41.2% during the 3rd quarter. Ashton Thomas Securities LLC now owns 3,782 shares of the company’s stock valued at $3,351,000 after purchasing an additional 1,103 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 4.7 %

Shares of LLY stock opened at $828.80 on Tuesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The stock has a market capitalization of $785.84 billion, a P/E ratio of 70.78, a P/E/G ratio of 1.40 and a beta of 0.34. The firm’s 50 day moving average is $827.73 and its 200 day moving average is $846.36.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its board has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Citigroup dropped their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, Morgan Stanley set a $1,146.00 target price on shares of Eli Lilly and Company in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.